Drug Database
TJ

TJ-15 (OGT)

✓ Approved

Tsumura · therapeutic agent

What is TJ-15?

TJ-15 is a therapeutic agent developed by Tsumura. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesOGT
CompanyTsumura
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Tsumura

Therapeutic Indications

TJ-15 is developed for 5 unique indications across 5 therapeutic areas.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersEczema✓ Approved
Gastrointestinal disordersGastritis✓ Approved
Vascular disordersHypertension✓ Approved
Psychiatric disordersObsessive-compulsive disorder✓ Approved
Nervous system disordersCerebral cyst haemorrhage✓ Approved

Related Research Articles

PubMedPharmacogenomics and personalized medicine2026-08-30

Low Frequency of HLA-B*15:02 in Northwest China: Implications for Carbamazepine-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Screening Strategies.

Wang Xu X, Yang Ping P, Rao Feng F, Wang Longnan L et al.

HLA-B*15:02 is an important genetic marker for predicting carbamazepine (CBZ)-induced Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN) in Asian populations. This descriptive pooled analysis aimed to characterize HLA-B*15:02 distribution in Northwest China and inform regional screening strategies. We genotyped HLA-B*15:02 via next-generation sequencing (NGS) in 98 healthy volunteers from Ningxia, and combined these data with 11 previously published studies (total N=3400) from Northwest China. Weighted means, medians, and interquartile ranges (IQR) were calculated by region and ethnicity, with Pearson's chi‑square tests for group comparisons (significance threshold: P < 0.05). The overall HLA-B*15:02 frequency was 1.81% (range: 0.00%-3.30%; IQR: 0.24-1.97%). Regional weighted frequencies were 2.12% (Qinghai), 1.98% (Shaanxi), 1.02% (Ningxia), and 0.38% (Xinjiang); ethnic frequencies ranged from 0% (Kazakh) to 2.28% (Hui). No significant regional (χ2 = 7.60, P = 0.055) or ethnic (χ2 = 7.35, P = 0.119) differences were observed, nor was there a significant difference between Han and other ethnic groups (P = 0.074). The overall frequency of HLA-B*15:02 in Northwest China is 1.81%, substantially lower than in South China, suggesting a lower expected yield of routine screening in this region.

PMID 42668977
Read full article →
PubMedThe journal of allergy and clinical immunology. Global2026-08-30

ALOX15-driven ω-6 fatty acid metabolism promotes type 2 inflammation in eosinophilic chronic rhinosinusitis with nasal polyps.

Sakashita Masafumi M, Kidoguchi Masanori M, Imoto Yoshimasa Y, Sato Yohei Y et al.

Local lipid metabolism contributes to immune homeostasis in the nasal mucosa and the pathogenesis of chronic rhinosinusitis. However, lipid mediator networks underlying eosinophilic chronic rhinosinusitis (ECRS) remain poorly defined. To characterize fatty acid-derived lipid mediator profiles in nasal polyps (NPs) from patients with and without ECRS and identify pathways associated with eosinophilic inflammation. Lipidomic profiling was performed using LC-MS/MS on NP tissues from patients with ECRS (n = 4) and without ECRS (n = 4). A total of 158 ω-6 and ω-3 fatty acid-derived lipid mediators were quantified. Arachidonate 15-lipoxygenase (ALOX15) pathway activity was evaluated by quantitative PCR and ELISA. ECRS NPs displayed a distinct lipidomic signature compared with non-ECRS NPs. ECRS NPs exhibited increased levels of proinflammatory ω-6 fatty acid metabolites, including 15-hydroxyeicosatetraenoic acid (15-HETE) and 13-hydroxyoctadecadienoic acid, along with elevated ALOX15 pathway products and higher ALOX15 mRNA expression. Anti-inflammatory specialized proresolving mediators, such as lipoxin A4, were also elevated within the ω-6 pathway, and lipoxin A4 levels correlated with 15-HETE levels. These patterns indicate the concurrent activation of pro- and anti-inflammatory pathways, with a predominance of ALOX15-driven ω-6 metabolites in ECRS. In contrast, the ω-3 fatty acid pathway showed only modest increases in 14,15-DiHETE and resolvin D2, suggesting a limited compensatory resolution response compared with the robust ALOX15-dependent ω-6 activity. ECRS NPs exhibit a skewed lipid mediator profile characterized by enhanced ALOX15-dependent ω-6 metabolism and insufficient resolution activity. This imbalance may underlie persistent type 2 inflammation in ECRS and suggests that targeting the 15-lipoxygenase pathway may offer therapeutic benefits.

PMID 42668469
Read full article →
PubMedPhotodiagnosis and photodynamic therapy2026-08-30

Choroidal microvascular heterogeneity across non-autoimmune type 2 diabetes mellitus subtypes defined by beta-cell function and insulin resistance: a wide-field Swept-Source OCTA study.

Wu Xiaoyan X, Li Qiong Q, Cui Yi Y, Xu Nuo N

To investigate the intergroup differences in choroidal thickness (CT), choroidal vascularity index (CVI), and choroidal vascular volume (CVV) across non-autoimmune type 2 diabetes mellitus (T2DM) subtypes defined by beta-cell function and insulin resistance. This cross-sectional study enrolled 22 healthy controls (22 eyes) and 85 T2DM patients (85 eyes). T2DM patients were categorized into 4 groups using K-means clustering: Severe Insulin-deficient Diabetes (SIDD) =22, Severe Insulin-resistant Diabetes (SIRD)=26, Mild Obesity-related Diabetes (MOD)=16, and Mild Age-related Diabetes (MARD)=21. CT, CVI, CVV were measured by widefield swept-source optical coherence tomography angiography (WSS-OCTA) across three concentric annular regions(0 - 10 mm, 10 - 15 mm, and 15 - 20 mm), subdivided into 12 sectors. Linear mixed-effects and multivariate regression models were constructed to evaluate intergroup differences. Compared with the control group, both CT and CVV decreased significantly in most of the 12 analyzed regions across all T2DM groups, whereas the MOD and SIRD groups exhibited no statistically significant global changes. In contrast, CVI exhibited pronounced spatial and subtype-specific heterogeneity. In the SIDD group, CVI decreased in most regions, with significant reductions in the nasal sector of the 0 - 10 mm annulus (P<0.01]), and in the nasal and inferior sectors of the 10 - 15 mm annulus (P<0.01] and -0.065 (P<0.01). Conversely, the SIRD group demonstrated a widespread increase in CVI, with significant increased in the nasal (P < 0.05), superior (P < 0.05), and temporal (P < 0.05]) sectors of the 15 - 20 mm annulus. Compared with CT and CVV, CVI shows the highest spatial heterogeneity. This indicates that divergent metabolic drivers may exert opposing effects on choroidal vascular remodeling. This subtype-specific characterization enhances our understanding of diabetic choroidopathy pathophysiology and holds potential for guiding personalized screening and therapeutic strategies.

PMID 42669328
Read full article →
PubMedJapanese journal of infectious diseases2026-08-30

Immunogenicity and Safety of the 9-valent Human Papillomavirus (HPV) Vaccine Administered as 2-Dose or 3-Dose Regimens in Japanese Boys and Girls Aged 9-15 Years.

Takeuchi Yuzuru Y, Yonekawa Motoharu M, Murata Shinya S, Nakagomi Mariko M et al.

A phase III open-label study evaluated the immunogenicity and safety of the 9-valent human papillomavirus (9vHPV) vaccine in Japanese boys and girls. Japanese boys aged 9-15 years (n = 105) received a 3-dose (Day 1, Month 2, and Month 6) regimen; Japanese boys (n = 104) and girls aged 9-14 years (n = 105) received a 2-dose (Day 1 and Month 6) regimen. Antibody responses to HPV6/11/16/18/31/33/45/52/58 were assessed at Month 7, 18, and 30 using a competitive Luminex immunoassay. Injection-site adverse events (AEs; Days 1 to 5 post-dose), systemic AEs (Days 1 to 15 post-dose), and serious AEs (duration of study) were assessed. At Month 7, for HPV types targeted by the 9vHPV vaccine, seroconversion rates were 100% in all three arms, and in cross-study comparisons with efficacy studies, anti-HPV geometric mean titers in boys were noninferior to those in Japanese men aged 16-26 years, and in girls were noninferior to those in Japanese women aged 16-26 years. Most injection-site AEs were mild to moderate in intensity. No deaths or vaccine-related serious AEs were observed. These results support immunobridging of efficacy findings in Japanese men and women to Japanese boys and girls. The 9vHPV vaccine was generally well tolerated.

PMID 42669546
Read full article →
PubMedJournal of interpersonal violence2026-08-30

Advancing the Longitudinal Measurement of Physical Aggression from Age 3 to 15: Applications of Moderated Non-Linear Factor Analysis.

Fix Rebecca L RL, Raghunathan Radhika S RS, Iris Luo Xiaoshuang X, Geller Amanda A

Physically aggressive behavior among children and adolescents is a longstanding concern, as documented in a large body of literature examining trajectories of aggressive behavior. However, aggression has been shown to present differently across the life course and is also likely to present differently across population subgroups, complexity that challenges the understanding and prevention of, and intervention in, problem behaviors. We therefore created covariate-informed trajectories of aggressive behaviors and identified subgroups representing heterogeneity in the development of girls' and boys' physically aggressive behaviors from ages 3 to 15 years. We used data from 3,263 families in the Future of Families and Child Well-being Study (waves 3-6, ages 3-15 years), a longitudinal birth cohort study following children born in large cities between 1998 and 2000 to mostly unmarried mothers. We used moderated non-linear factor analysis to generate factor scores of physically aggressive behaviors over time, separately for boys and girls, and then ran sex-separated latent growth models using the covariate-informed factor scores. Both girls and boys had three-class change trajectories. For adolescent girls, there is just one trajectory toward physically aggressive behavior (with the third classification as Desistors). For adolescent boys, there are two trajectories toward aggressive behavior (including Adolescent Onset). While universal programming that is not gender-responsive can meet the needs of young people who were classified as Persistors or in the Low Aggression group, we observed unique possible points of intervention and sex-specific needs. In response, we advise on interventions for young people, adults in youth-serving organizations, and structural-level considerations.

PMID 42668415
Read full article →
PubMedZhonghua wai ke za zhi [Chinese journal of surgery]2026-08-30

[Application of JSGPM classification in pancreaticobiliary maljunction].

Weng M Z MZ, Weng H H, Wang Y Y, Wu W J WJ et al.

Objective: To evaluate the clinical value of the Japanese Study Group on Pancreaticobiliary Maljunction(JSGPM) classification in the diagnosis and treatment of pancreaticobiliary maljunction (PBM). Methods: A retrospective cohort analysis was conducted on 103 patients diagnosed with PBM via endoscopic retrograde cholangiopancreatography at the Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine from January 2010 to September 2018. There were 32 male cases and 71 female cases; the age (M(IQR)) was 5.1 (39.0) years (range: 2.2 to 56.1 years), with 74 cases aged <12 years and 29 cases aged ≥12 years.The distribution characteristics, clinical manifestations, and treatment strategies of different JSGPM subtypes were compared between pediatric (<12 years) and adolescent/adult (≥12 years) patients. Normally distributed quantitative data were compared between two groups using the independent samples t-test, and among multiple groups using analysis of variance (ANOVA). Skewed quantitative data were compared using non-parametric tests. Categorical variables were compared using the χ² test or Fisher's exact test. Results: Among the 103 PBM patients, JSGPM classified 40 cases as type A (39.2%), 31 cases as type B (30.4%), 25 cases as type C (24.5%), and 6 as type D (5.9%), with no unclassifiable cases. Among patients aged ≥12 years, the incidence of type B PBM was higher than that in children <12 years (51.7% (15/29) vs. 21.6% (16/74); χ²=8.974, P<0.01), and type B was the predominant subtype without concurrent common bile duct dilation (≥12 years vs. <12 years: 12/15 vs. 7/16). Among the 7 pediatric cases (7/16) and 12 adult patients (12/15) with type B PBM without concurrent common bile duct dilation, none underwent extrahepatic bile duct resection; instead, they received only endoscopic sphincterotomy plus cholecystectomy. All patients were followed up for (36±26) months (range: 6 to 96 months), with no recurrence of biliary tract infections, obstructive jaundice, or pancreatitis. Conclusions: The JSGPM classification is concise, practical, and highly correlated with clinical features and prognostic risks, providing clear guidance for individualized diagnosis and treatment. This classification helps identify high-risk type B PBM patients and guides the implementation of precise preventive strategies, avoiding undertreatment or overtreatment.

PMID 42669449
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about TJ-15